<DOC>
	<DOCNO>NCT02171156</DOCNO>
	<brief_summary>To provide early access evaluate safety tolerability nintedanib patient idiopathic pulmonary fibrosis ( IPF ) .</brief_summary>
	<brief_title>Expanded Access Program Nintedanib Patients With Idiopathic Pulmonary Fibrosis ( EAP )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : 1 . Signed Informed Consent consistent ICHGCP local law sign prior entry trial ; 2 . Male female patient age &gt; =40 year Visit 1 ; 3 . IPF diagnosis base upon American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) /Japanese Respiratory Society ( JRS ) /Latin American Thoracic Society ( ALAT ) IPF 2011 guideline within 5 year visit 1 ; 4 . Carbon monoxide diffuse capacity ( DLCO ) ( correct Haemoglobin ( Hb ) ) : 30 % 79 % predict normal , per institutional standard clinic site , Visit 1 ; 5 . Forced Vital Capacity ( FVC ) &gt; = 50 % predict normal , per institutional standard clinic site , Visit 1 . Exclusion criterion : 1 . Eligible participate participate ongoing actively accrue clinical trial nintedanib treatment IPF . Laboratory parameter Visit 1 must satisfy entry criterion show . Abnormal laboratory parameter may retested measurement error suspect ( e.g. , abnormal result test recent history patient related clinical sign ) . The result retest report within Screening period ( i.e. , 28 day sign informed consent form ) . 2 . ALT , AST &gt; 1.5 time upper limit normal ( ULN ) ; 3 . Total Bilirubin &gt; 1.5 time upper limit normal ( ULN ) ; 4 . Bleeding risk : 1. patient require : fibrinolysis , fulldose therapeutic anticoagulation ( e.g . vitamin K antagonist , dabigatran , heparin , hirudin , etc . ) , highdose antiplatelet therapy . Exceptions : prophylactic low dose heparin heparin flush need maintenance indwell intravenous device ( e.g. , enoxaparin 4000 IU s.c. per day ) prophylactic use antiplatelet therapy ( e.g. , acetylsalicylic acid 325 mg/d , clopidogrel 75 mg/d , equivalent dos antiplatelet therapy ) ; 2. history hemorrhagic central nervous system ( CNS ) event within 12 month Visit 1 ; 3. follow within 3 month Visit 1 ; hemoptysis haematuria active gastrointestinal bleeding ulcer major injury surgery 4. coagulation parameter : international normalised ratio ( INR ) &gt; 2 prothrombin time ( PT ) partial thromboplastin time ( PTT ) &gt; 150 % institutional upper limit normal ( ULN ) 5 . Planned major surgery within next 3 month , include lung transplantation , major abdominal major intestinal surgery ; 6 . Thrombotic risk : 1. know inherited predisposition thrombosis 2. history thrombotic event ( include stroke transient ischemic attack ) within 12 month Visit 1 ; 7 . Cardiac disease : 1 . Myocardial infarction within 6 month Visit 1 2 . Unstable angina within 1 month Visit 1 ; 8 . Current plan usage ( course trial ) investigational drug course trial ; 9 . Current plan treatment ( course trial ) : pirfenidone , azathioprine , cyclophosphamide , cyclosporine , prednisone &gt; 15 mg daily &gt; 30 mg every 2 day OR equivalent dose oral corticosteroid , well list exclusion criterion # 4 ( bleed risk ) ; 10 . Permanent discontinuation nintedanib within clinical trial , due adverse event consider drugrelated ; 11 . Known hypersensitivity nintedanib excipients ; 12 . A disease condition opinion treat physician may put patient risk participation trial limit patient 's ability participate trial ; 13 . Alcohol drug abuse opinion treat physician would interfere participation ; 14 . Women ( childbearing potential ) unwilling use acceptable method contraception ; 15 . Pregnancy breast feeding ( female patient must negative pregnancy test ( ÃŸHCG test urine serum ) prior commence trial treatment ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>